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Abstract 
Atrial fibrillation (AF), the most common cardiac arrhythmia in persons over age 65, is 
associated with an increased stroke risk necessitating the need for long-term oral anticoagulation 
for risk reduction. With the introduction of direct thrombin and factor Xa inhibitors in the US 
since 2010, these novel oral anticoagulants (NOACs) are increasingly being prescribed, 
replacing the use of warfarin, a vitamin K antagonist. AF catheter ablation (CA), an elective 
procedure requiring femoral vascular access is a treatment for drug refractory and persistent AF. 
Bedrest, limb immobilization, and limited head of bed elevation are nursing measures utilized 
following femoral venous, and sometimes arterial, sheath removal and hemostasis. Limited 
research is available on the appropriate duration of bedrest to minimize bleeding complications 
associated with AF ablation in patients who use NOACs. The purpose of this quality 
improvement project was to compare and evaluate the effect of bedrest duration on post-
procedure bleeding outcomes, urinary complaints, and back pain among patients taking NOACs 
while undergoing AFCA.  
Thirty patients undergoing elective AFCA on NOACs were orally consented to 
participate in the study and placed on shortened (8 hours) or prolonged (>8 hours) bedrest 
following vascular hemostasis. Outcome measurements included bleeding after ambulation, back 
pain, and urinary complaints. Fifteen patients (50%) were on shortened bedrest and 15 (50%) 
were on prolonged bedrest. No statistically significant difference in bleeding, urinary complaints, 
or back pain were found. Since there is no clear advantage to prolonged bedrest for patients on 
NOACS after an AFCA procedure, clinicians should consider this when deciding on bedrest 
duration for their patients. 
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Chapter I: Introduction 
 Atrial fibrillation (AF), irregular rapid contractions of the atria asynchronously from 
ventricular contractions, is the most common cardiac arrhythmia. With an estimated prevalence 
of 3.4 million persons in 2010, 12 million people are predicted to have the problem by 2050 in 
the United States (US) alone (Centers for Disease Control [CDC], 2010; Lloyd-Jones et al., 
2011; Naccarelli, Johnston, Dalal, Lin & Patel, 2012). One-third of hospitalizations are a result 
of cardiac arrhythmias, with a 66% reported increase in hospitalizations for AF over the past two 
decades. Advancing age, chronic cardiovascular disease, and more diagnoses through outpatient 
telemetry monitoring has been cited for the increase in numbers (CDC, 2010; Lloyd-Jones et al., 
2011; Fuster et al., 2006).  Treatment of AF represents a significant health care burden to both 
patients and healthcare providers. The estimated cost of the treatment of atrial fibrillation of US 
patients in 2005 was $6.65 billion per year, including the costs of hospitalization, in- and 
outpatient health care, and medications (Coyne, Paramore, Granady, Mercader, Reynolds, & 
Zimetbaum, 2006). Hospitalization costs comprise up to 70% of costs spent on treatment of AF 
(Gorenek, & Kudaiberdieva, 2013). The estimated average cost in the US is $3600 annually per 
patient.  The incidence of atrial fibrillation increases with age. The median age for patients with 
atrial fibrillation is 66.8 years for men and 74.6 years for women (CDC, 2010).  
 The mortality rate from AF as either the primary or an underlying cause of death has been 
increasing for more than two decades.  Thromboembolic (TE) cerebral events and congestive 
heart failure (HF) represent two of the most common and costly complications of AF, and are 
associated with increased mortality (CDC, 2010).  Stroke risk is increased two to seven-fold in 
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persons with AF with an annual ischemic stroke risk of approximately five percent annually. AF 
may cause up to 15 to 20 % of ischemic strokes in the U.S. and increases one’s risk by five times 
(CDC, 2010; Fang et al., 2008).   
 Thrombus formation in AF, attributed to low flow, or stasis of atrial blood, most often 
accumulated in the left atrial appendage, is associated with cerebral TEs in AF. Known atrial 
stunning and stasis occurs with cardioversion from AF to sinus rhythm (SR), whether 
spontaneous, chemical or electrical (Fuster et al, 2006).  Progressive improvement of atrial 
stunning usually occurs with conversion over days to several weeks, and varies in intensity based 
on severity of heart disease and duration of AF.  This thrombus accumulation propensity with AF 
is the cornerstone of the stroke risk and need management with antithrombotics. 
Treatment of Atrial Fibrillation 
Treatment of AF is predicated on symptom management, prevention of TE, and restoring 
a normal rhythm (Fuster et al., 2006).  Standard treatment options of AF include rate control and 
rhythm control strategies including anti-arrhythmic drug therapy (AAD), and direct current 
cardioversion (DCC).  Atrial fibrillation catheter ablation (AFCA) has emerged over the last 
decade as a viable rhythm control treatment option, usually as a second line treatment when 
failure has occurred and the individual is considered drug refractory AF (Calkins & Dewire, 
2013).   
Anticoagulation 
Persons with diagnosed nonvalvular AF are administered oral anticoagulants (OAC) for 
thromboprophylaxis. Historically, OAC therapy has been limited to warfarin, a vitamin K 
antagonist (VKA) with many unfavorable qualities and limitations including food-food and food-
drug interactions, a narrow therapeutic index, slow onset of action, a long half-life, major 
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bleeding, and the need for routine laboratory blood testing and monitoring of a patient's 
international normalized ration (INR) blood level for dose titration.  For these reasons, many 
patients have difficulty with maintaining a time in therapeutic range (TTR) and are at increased 
stroke risk in AF despite taking an OAC (Camm et al, 2012; Fuster et al., 2011; Maan et al., 
2012).  Since the Food and Drug Administration (FDA) approval of dabigatran etexilate, a direct 
thrombin inhibitor, the options for OAC have exploded, and the agents are termed novel oral 
anticoagulants (NOAC).  
 Dabigatran was the first new OAC available in more than 50 years.  As of this writing, 
rivaroxaban and apixaban, oral direct Factor Xa inhibitors, have also received FDA approval in 
the U.S. for stroke prevention in nonvalvular AF.  Like dabigatran, the Factor Xa inhibitor 
NOACs entered the marketplace following the release of several head-to-head trials of warfarin 
and the NOACs in which they were found to be more efficacious in stroke and systemic embolic 
prevention, carry a lower risk of intracranial bleeding, and have a favorable safety profile in AF 
patients (Miller, Grandi, Shimony, Filion, & Eisenberg, 2012). In 2012, the European Society of 
Cardiology (ESC) updated their 2010 guidelines for atrial fibrillation, concluding that NOACs 
offer better efficacy, safety, and convenience compared to OAC with VKA's. Thus, 
where an OAC is recommended, one of the NOACs-either a direct thrombin inhibitor 
(dabigatran) or an oral factor Xa inhibitor (rivaroxaban, apixaban), should be considered 
instead of adjusted dose VKA (INR 2-3) for most patients with AF. (Camm et al., 2012, 
p. 2731) 
There was no recommendation for one of the NOACs over another due to insufficient evidence.  
 With the advent of NOACs, patients and providers have alternative options. Because 
NOACs offer a more predictable pharmacokinetic profile than that of warfarin, there is no need 
for monitoring the INR level and adjusting the dose to achieve a target range, making this a more 
acceptable therapy. Evolutionary changes in stroke risk prophylaxis for AF with these NOACs 
offer patients many options to choose from based on personal preferences and risk profiles. The 
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NOACs do not have a safe and acceptable antidote, unlike warfarin. This elicits fear and 
uncertainty in the event of major bleeding. For these reasons, many practitioners and patients are 
slow and cautious when transitioning to their use. Ongoing safety and efficacy research will need 
to guide clinical practice. With many AF patients now taking NOACs, preventive and effective 
management of bleeding complications and inquiries are necessary of the providers to stay 
abreast of evolving issues related to NOAC use as it becomes available.  
Pharmacologic therapy 
Either a rate or rhythm control strategy is acceptable treatment of symptomatic AF, and 
has similar mortality outcomes (Wyse et al., 2002). Rate control is attained with beta-blockers, 
nondihydropyridine calcium channel antagonists, digitalis, alone or in combination with 
amiodarone. Rhythm control strategies for pharmacologic cardioversion or maintenance of sinus 
rhythm (SR) may include flecainide, dofetilide, propafenone, and ibutilide. Quinidine or 
procainamide administration may be considered but the usefulness is not well established. 
Digoxin and sotalol are not recommended for pharmacological cardioversion. Hospital 
admission and monitoring is required for initiation of quinidine, procainamide, disopyramide, 
and dofetilide for pharmacological cardioversion from AF to SR (Fuster et al., 2006). 
Catheter ablation 
Catheter-based atrial fibrillation ablation, which began in the late 1980's, is now one of 
the most performed ablation procedures in large US hospitals (Calkins & Dewire, 2013).  The 
procedure is performed in the laboratory under anesthesia sedation.  With ablation catheters and 
mapping systems, the goal of AFCA is eradication of AF through pulmonary vein isolation (PVI) 
using radiofrequency or cryoablation of the AF pathways. Vascular access is obtained via the 
femoral vein with adjuvant femoral artery monitoring in some cases.  The femoral sheaths are 
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removed following the procedure in a recovery holding area when the physician and staff deem 
the patient hemodynamically stable with an acceptable activated clotting time.  Achieving groin 
hemostasis is traditionally performed by manual compression and use of FemoStop compression 
devices.  The patient is confined to bed for a specified time period with immobilization of the 
affected extremities for management of vascular access bleeding complications.  Further patient 
activity restrictions include head of bed (HOB) limitations and use of indwelling urinary 
catheters in lieu of bathroom privileges.  
 AFCA risks include pericardial effusion, vascular access complications requiring surgery 
or blood transfusion, cardiac tamponade, hemothorax, stroke, sepsis, pneumonia, phrenic nerve 
injury and paralysis, esophageal injury, atrio-esophageal fistula, PV stenosis, radiation exposure, 
acute coronary artery occlusion, periesophageal vagal injury, mitral valve trauma, post 
procedural arrhythmias (Calkins et al., 2007).  The rate of complications varies based on many 
factors with bleeding related complications the most common. Anticoagulation further 
compounds the bleeding issue, as it is necessary to prevent stroke.  Bleeding complications may 
be compounded due to need for aggressive intraprocedural anticoagulation with intravenous (IV) 
unfractionated heparin to minimize catheter clotting and thromboembolic events.  With 
additional use of NOACs, and their lack of a reliable antidote, bleeding complications are 
increasingly worrisome for patients and providers.  
Overview of the Problem 
 Bleeding complications are long recognized and associated with femoral vascular access 
in percutaneous cardiac procedures including catheter ablation, coronary angiography, and 
percutaneous coronary interventions (PCI) (Merriweather & Suzbach-Hoke, 2012; Mohammady, 
Heidari, Sari, Zolfaghari, & Janani, 2013; Prudente et al., 2009; Raviele et al., 2012).  Bedrest, 
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compression, and lower extremity immobilization are commonly used nursing management tools 
to maintain femoral access hemostasis and minimize complications of bleeding.  Femoral 
vascular access bleeding complications will manifest as bruising, hematoma, pseudoaneurysm, 
and arteriovenous fistula.  More serious and life threatening complications of cardiac tamponade 
and hemothorax may also occur rarely.  Complications can lead to longer hospitalizations, 
surgical procedures, and increased costs (Raviele et al, 2012, Shoulders-Odom, 2006).   
 Early ambulation of patients post-cardiac catheterization and PCI is widely recognized to 
be associated with fewer adverse outcomes which may include deep vein thrombosis, back pain, 
difficulties with eating, drinking, and voiding, and overall patient dissatisfaction (Schiks et al., 
2008).  Post-PCI or AFCA bedrest may vary from 4 to 18 hours after femoral access sheath 
removal, with patients taking anticoagulants.  Both groups of patients undergo anticoagulation in 
conjunction with their respective cardiac procedures and are cared for by the same nursing staff.  
No consistency or evidence exists on the optimal time to minimize bleeding risk and decrease 
adverse outcomes of prolonged bedrest. Very limited, to no research, is available on post-
operative bedrest recommendations to mitigate bleeding complications in the post-AFCA patient 
population on NOACs.   
Purpose of Project 
 The project purpose was to evaluate primary and secondary outcomes based on the 
duration of bedrest in patients undergoing AFCA on NOACs.  Primary outcome measurements 
will include bleeding complications:  bruising, hematoma formation, pseudoaneurysm and 
arteriovenous fistula formation. Secondary outcomes will include urinary complaints including 
need for catheterization, hematuria, frequency, urgency, and back pain while on bedrest. The 
goal of this project was to explore bedrest duration effects in order to minimize the patient 
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discomfort of prolonged bedrest and urinary catheters, standardize the postoperative care of 
AFCA patients on NOACs, while maintaining safe practice through implementation of a 
standardized post-procedural protocol for bedrest and activity restrictions in patients on NOACs. 
Definitions 
Atrial fibrillation 
For the purposes of this project, AF was defined as paroxysmal or persistent in character 
as classified in ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial 
Fibrillation (Fuster et al., 2006). 
Anticoagulation 
 For the purposes of this project, anticoagulation refers to both oral and IV 
antithrombotics, but did not include antiplatelet medications such as clopidogrel or aspirin.  
Bleeding Complication 
A bleeding complication was measured as bleeding requiring reapplication of manual 
pressure and/or pressure dressing or device, a hematoma larger than 5 centimeter (cm) in width, 
or blood loss requiring transfusion, additional bedrest, additional testing,  or increased length of 
hospital stay. 
Shortened Bedrest 
For the purposes of this project, shortened bedrest was eight hours or less. 
Prolonged Bedrest 
For the purposes of this project, prolonged bedrest was greater than eight hours. 
 8 
Urinary Discomfort 
For purposes of this project, urinary discomfort was defined as difficulty with urination 
requiring reinsertion of catheterization, patient reported burning or bleeding with urination. 
Back Pain 
For purposes of this project, back pain was assessed by nursing with the widely used 1 to 
10 point pain scale, and will be classified as mild (0-3), moderate (4-6), or severe (7-10). 
Summary 
 Atrial fibrillation and management with CA is growing exponentially as patients seek 
curative treatment of the highly prevalent condition. With the attractiveness and favorable 
outcomes of NOACs for ease of use in stroke risk reduction, evidence based care of these 
patients is necessary for optimal outcomes. AFCA, like percutaneous transfemoral coronary 
interventions, requires femoral vascular access and sheath removal, maintenance of hemostasis, 
and management of bleeding complications.  While research abounds on optimal time for bedrest 
and early ambulation in the cardiac catheterization and PCI patient population, very little is 
available on the newer AFCA patient needs.  This project will evaluate the bleeding outcomes of 
varying post-procedural bed rest times in AFCA patients taking NOACs, in hopes of adding to 
the limited body of knowledge currently available in this arena. 
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Chapter 2: Literature Review 
 A brief overview of the bedrest literature is followed by a description of the search 
strategies and criteria employed to determine the use of bedrest and immobilization in prevention 
of bleeding complications following femoral vascular access in cardiac procedures. This is 
followed by a synthesis of the evidence and implications for the direction of the project. 
Bedrest Following Procedures Requiring Femoral Vascular Access 
 Although bedrest and affected lower limb immobilization is the accepted practice 
following invasive femoral artery and vein access procedures following sheath removal and 
hemostasis, prolonged bedrest and immobilization have been cited with increased patient 
dissatisfaction, back pain, and difficulty with urination with resultant urinary catheterizations 
(Merriweather & Suzbach-Hoke, 2012; Shoulders-Odom, 2006).  The existing cardiac 
catheterization laboratory guidelines addressing bedrest duration are abbreviated and general, 
lacking in specificity. Sheath size is the major determinant of bedrest duration and commonly 
ranges from 1 to 2 hours for 4 and 5 French (F) sheaths, and 2 to 4 hours for 6 to 8 F sizes 
(Bashore et al., 2012).  It is understood that certain patient traits including obesity, female 
gender, and uncontrolled hypertension may place an individual at increased bleeding risk 
following procedures requiring femoral vascular access.  Further activities that may increase 
bleeding risk are OAC use, bleeding tendencies, coughing, vomiting, straining with elimination, 
difficult vascular access, multiple femoral vascular procedures, larger sheath sizes, operator 
experience, hemostasis techniques, use of vascular closure devices, and longer duration of 
sheaths (Baman et al., 2011). Despite the lack of hard evidence for extended bedrest, varying 
bedrest duration exists in practice.  
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 Very little research is available on the appropriate amount and role of bedrest duration in 
avoidance of bleeding complications in the AFCA population.  However, there is a substantial 
body of evidence, including meta-analyses, randomized clinical trials (RCTs), and systematic 
reviews, on other diagnostic and therapeutic procedures requiring femoral access, including 
diagnostic cardiac catheterization (DCC), percutaneous coronary intervention (PCI), and 
percutaneous transluminal coronary angiogram (PTCA). Thus, the evidence-base for this project 
is post-procedure bedrest duration of patients undergoing DCC, PTCA, and PCI.  
Search Strategies 
 The search strategy was driven by the following PICO question:  In patients on NOACs 
who undergo femoral access procedures, does prolonged bedrest improve outcomes and 
satisfaction with care?   
 P (population):  Patients taking NOACs 
 I (interest):  Prolonged post-procedure bedrest (12 hours or longer) 
 C (comparison):  Traditional post-procedure bedrest (<8 hours)  
 O (outcome):  Bleeding complications, hematoma, AVF, pseudoaneurysm, back pain, 
 urinary complaints, patient satisfaction 
CINAHL, PubMed, and the Cochrane Library databases were searched using various 
combinations of keywords including femoral vascular access, catheter ablation, cardiac 
catheteriz(s)ation, bedrest, ambulation, bleeding, hematoma, anticoagulation, electrophysiology 
study, and atrial fibrillation. On initial searches all dates and study types were searched, then 
narrowed down to include the past five years, 2008 to 2013, with English language the only limit 
selected.  Further limited searches including searching for randomized controlled trials (RCTs), 
meta-analyses, and systematic review articles and manually reviewing the reference lists of 
selected high quality studies.  
 11 
 Upon review of articles regarding bedrest and bleeding complications following femoral 
vascular access for DCC, PTCA, PCI, and EP studies, the author excluded DCC studies from 
synthesis, due to the simplicity of the procedure compared to the more involved PTCA, PCI, or 
electrophysiology study (EPS) or AFCA.  The DCC typically uses a smaller vascular access 
sheath or catheter size (4 French [F] or 6 F), and is of shorter duration than when a patient 
receives an intervention of balloon angioplasty in PTCA, or stent deployment in PCI.  In the 
PTCA and PCI patients, the larger sheath and catheter sizes required for vascular access and 
intervention, and procedure duration are more akin to the complex EPS and AFCA procedures.  
The included studies for synthesis examined outcomes of femoral access site bleeding and 
hematoma, patient comfort, and some included urinary discomfort as a secondary outcome 
related to bedrest duration or ambulation time. Figure 1 depicts the flow of the literature search. 
Literature Synthesis 
 Seminal research on the role of bedrest duration consisted of a series of four time-in-bed 
studies (TIBS). The first two studies were done with patients undergoing DCC, first reducing 
bedrest duration from 12 to 6 hours (Keeling, Knight, Taylor, & Nordt, 1994), then, reducing 
time-in-bed from 6 to 4 hours (Keeling, Taylor, Nordt, Powers, Fisher, 1996).  These studies 
supported evidence that shorter time-in-bed following DCC was not associated with an increased   
risk of bleeding. Patient satisfaction was also improved with shorter post-DCC time-in-bed. 
Similar results were found with later studies with patients undergoing PTCA and reduced bedrest 
from 6 to 4 hours (Keeling, Fisher, Haugh, Powers, Turner, 2000) and patients undergoing EPS 
with reduced bedrest from 4 to 2 hours (Gianakos, Keeling, Haines & Haugh, 2004).  
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Figure 2.1. Flow diagram of article selection process.  
Articles screened by  
title and abstract 
Manuscript review and 
application of inclusion 
criteria 
Excluded (n = 6) 
Reason 1: Use of vascular 
closure device 
  2: Independent variable 
of bedrest duration not 
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Studies included for 
synthesis 
(n = 13) 
Search results combined after 
duplicates removed (n = 1048) 
Included for manuscript 
review (n = 19) 
Excluded (n = 1029 ) 
Reason 1: No bedrest or 
activity outcome 
Reason 2: Bleeding outcome 
not included 
Reason 3: Evaluation of 
vascular closure device 
 
 
Reason 4: Pregnancy 
 
 
Literature Search Databases: CINAHL, 
PubMed, Cochrane Library 
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Research syntheses 
Since these seminal studies, a plethora of research has been done in this area. Much of the 
research has been synthesized in several meta-analyses and systematic reviews (see Table 2.1). 
Three recent meta-analyses of a total of 40 RCTs on shortened bedrest duration following 
femoral sheath removal in 10,658 patients undergoing DCC or PCI procedures found no effect 
on bleeding or hematoma formation (Kim et al., 2013; Mohammady Heidari, Sari, Zolfaghari, & 
Janani, 2013; Tongsai & Thamlikitkul, 2012). These findings echoed those of three earlier 
systematic reviews of experimental, quasi-experimental, and descriptive studies (Chair et al., 
2008; Reynolds, Waterhouse, & Miller, 2001; Vaught & Ostrow, 2001). 
Experimental and Quasi-experimental Studies 
Ongoing research continues to provide evidence of the safety of early ambulation. A total 
of nine studies were reviewed and synthesized (see Table 2.2). Table 2.3 provides the criteria 
used to determine the strength and quality of the evidence. 
Similar to the previous research syntheses, there was no difference in bleeding or 
vascular complications with shortened bedrest duration. In one instance, there was a non-
significant increase in bleeding in the longer bedrest (Tagney & Lackie, 2005). There was no 
difference in urinary complaints or back pain among the groups. Patient satisfaction was not 
specific to bedrest duration in the included study. 
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Table 2.1 
Research Syntheses of Bedrest Evidence 
Author 
(Year) 
Method Sample Intervention Outcome Measurement Conclusions 
Kim et al. 
(2013) 
Meta-analysis 15 RCTs or quasi-
experimental studies with 
4,785 pts undergoing PCI 
 
Early ambulation 
 
Vascular complications: 
hematoma formation and 
hemorrhage at puncture 
site 
No increase in RR ratio of the 
incidence of hematoma formation nor 
bleeding at the puncture site based on 
early ambulaiton 
 
Mohammady 
et al. (2013) 
Systematic 
review and 
meta-analysis 
20 RCT's or quasi-
experimental studies with 
4019 pts undergoing DCC 
 
Different durations (2-
24 h) of bedrest before 
ambulation 
Vascular complications 
Pain 
Urinary discomfort 
Patient satisfaction; 
 
Early ambulation (2-3h) had no 
significant effect on incidence of 
vascular complications (hematomas 
reported 7.6% (268 occurrences) and 
bleeding 2.2% (47 occurrences); 
 back pain was lower in shorter 
bedrest; decreased urinary discomfort 
at 4h compared to 12-24 h (mean 
difference: -1.48: 95% CI: -2.37,- 
0.59)  
Tongsai & 
Thamlikitkul(
2012)  
Meta-analysis 5 RCTs with 1,854 pts 
undergoing  PCI  
 
Early ambulation (2-
4H  vs Late 
ambulation (6-10h):  
Vascular complications: 
bleeding, hematoma  
Pooled RR of hematoma was 0.82 
(95% CI, 0.53-1.28); 
Pooled RR of bleeding was 1.77(95% 
CI, 0.87-3.59) 
Early ambulation after PCI was not 
associated with an increased risk of 
hematoma or bleeding and comfired 
the findings of earlier studies 
recommending reduced time in bed 
following sheath removal from 6-10h 
to 2-4h 
Chair et al. 
(2008) 
Systematic 
review 
18 RCTs or quasi-
experimental studies with 
4,294 pts undergoing 
DCC  
 
Varying bedrest 
duration 
Vascular complications: 
bleeding, hematoma, 
bruising, pseudoaneurysm 
Back pain 
Groin pain 
Urinary discomfort 
Patient satisfaction 
No benefit related to bleeding and 
hematoma in longer than 3h bedrest; 
Less back pain in groups <6h bedrest; 
Methodological deficiencies in 
evidence base for generalizability of 
studies; Standardized, validated tool 
needed for hematoma measurement; 
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Author 
(Year) 
Method Sample Intervention Outcome Measurement Conclusions 
Reynolds et al. 
(2001) 
 Systematic 
review 
8 experimental, quasi-
experimental, and 
descriptive, studies with 
1,352 pts undergoing  
PTCA  
1 survey of 100 hospitals  
Early ambulation; 
 
Vascular complications: 
bleeding, hematoma  
Pain, comfort, 
Patient satisfaction 
Little existing evidence based research 
existing; Further large scale studies 
studies to guide post-PTCA on HOB 
elevation, walking, and patient 
comfort  
Vaught & 
Ostrow (2001) 
Systematic 
review  
5 experimental, quais-
experimental, and 
descriptive studies of 235 
pts  undergoing PTCA 
1 survey of 70 hospitals 
Bedrest duration Vascular complications: 
bleeding, hematoma  
Pain 
Patient satisfaction 
Decrease in hours of bedrest is safe 
following PTCA; more research is 
needed on specific post-procedure 
interventions and research articles 
needed on protocols; reliable and 
valid tool to measure bleeding and 
hematoma formation; universal pain 
scale needed;  
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Table 2.2 
 
Randomized Controlled Trials and Quasi-experimental Studies of Bedrest Post Femoral Access Procedure 
Author 
(Year) 
Method Sample 
Intervention/ 
Control 
Outcomes and Measures Results 
Quality of 
Evidence 
Chair et 
al. (2012) 
RCT-single 
blinded 
Pts undergoing DCC 
with unknown sheath 
size  
IG: n= 63 
CG: n= 74 
 
IG = 4h bedrest 
CG = 12-24h bedrest 
Vascular complications 
 
Pain 
 
 
 
 
Urinary discomfort 
 
 
 
 
Patient satisfaction 
1 pt in CG with bleeding 
Less back pain at 8 hours for 
IG (OR=0.19, 95% CI, 
0.08-0.45, p<0.001); 
 
Less "very or unbearable 
urination discomfort" in IG 
than CG (OR=0.35, 95% CI, 
0.14-0.90, p=0.03) 
 
Patient satisfaction no 
difference 
 
Level I B 
Gianakos 
et al. 
(2004) 
RCT  Pts undergoing  EP 
with 8F or smaller 
sheath 
IG: n=31 
CG: n= 37 
 
IG = 2h bedrest 
CG = 4h bedrest 
Bleeding 
 
 
Back pain 
 
 
Patient satisfaction 
 
 
No difference in bleeding 
incidence among groups 
 
Back pain in 2 pts in CG and 
1 pt in IG 
 
Patient satisfaction findings 
unclear as pts rated overall 
care and not specific to 
bedrest duration 
Level II C 
 
Keeling et 
al. (1994) 
RCT Pts undergoing DCC 
with unknown sheath 
size 
IG = 6h bedrest 
CG = 12 h bedrest 
Bleeding No difference in bleeding 
incidence among groups 
Level II C 
Keeling et 
al. (1996) 
RCT Pts undergoing DCC 
with unknown sheath 
size 
IG = 4h bedrest 
CG = 6h bedrest 
Bleeding No difference in bleeding 
among the groups 
Level II C 
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Author 
(Year) 
Method Sample 
Intervention/ 
Control 
Outcomes and Measures Results 
Quality of 
Evidence 
Keeling et 
al. (2000) 
RCT  Pts undergoing  PTCA  
with 8F catheter 
primarily 
 
IG: n=51 
CG: n= 20 
 
IG = 4h bedrest 
CG = 6h bedrest 
Bleeding 
 
 
 
98% of pts did not bleed; 
Bleeding was associated 
with higher ACT and re-
procedures 
Level II C 
Searle & 
Hoff 
(2000) 
Quasi-
experimental 
Pts undergoing DCC 
with unknown sheath 
size 
IG: n= 680 
CG: n=696 
 
IG = 2h bedrest 
CG = 3h bedrest 
Bleeding or hematoma at 
discharge and 1 week post 
 
 
IG bleeding in 28 (4%); 
CG bleeding in 26 (4%); 
IG bruise at 1 wk- 464 
(74%); 
CG bruise at 1 wk-438 
(73%); 
Late hematoma formation 
less in IG (p<0.001) and no 
increase in early bleeds or 
hematoma formation 
Level III B 
Schiks et 
al. (2008) 
Quasi-
experimental 
Patients undergoing 
PCI or fractional flow 
reserve (FFR) with 6F 
sheath  
IG: n= 329 
CG: n = 202  
 
IG = 4h bedrest 
CG = 10h bedrest 
Puncture site complications: 
hematoma, bleeding, 
pseudoaneurysm, AVF 
 
Patient comfort 
 
 
9 puncture site complications 
in IG (2.7%) and 6 in CG 
(3.0%) p=0.002; 
 
Patient comfort not 
statistically significantly 
different in groups 
Level II A 
Tagney & 
Lackie 
(2005) 
RCT Patients undergoing 
DCC or PTCA  with 6F 
sheath size 
IG: n = 176 
CG: n = 195 
 
IG = 3h bedrest 
CG = 6h bedrest 
Bleeding  
 
 
 
 
 
Hematoma 
 
 
Bleeding complications 
increased from 5(2.6%) in 
CG  to 11(6.3%) in IG-not 
statistically significant 
(p=o.333);  
 
Hematomas: 29 (14.8%) in 
IG; 19 (10.8%) in CG;  
Level I B 
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Table 2.3 
Appraising the Strength and Quality of the Research Evidence 
Strength of Research Evidence Rating Scheme 
Level Type of Evidence 
I Evidence obtained from an experimental study/randomized controlled trial (RCT) or 
meta-analysis of RCTs 
II Evidence obtained from a quasi-experimental study (cohort study) 
III Evidence obtained from a non-experimental study, qualitative study, or meta-synthesis 
Quality Rating Scheme for Research Evidence  
Grade Research Evidence 
A = High Consistent results with sufficient sample, adequate control, and definitive conclusions; 
consistent recommendations based on extensive literature review that includes 
thoughtful reference to scientific evidence 
B = Good Reasonably consistent results; sufficient sample, some control, with fairly definitive 
conclusions; reasonably consistent recommendations based on fairly comprehensive 
literature review that includes some reference to  scientific evidence 
C = Low 
Major Flaws 
Little evidence with inconsistent results; insufficient sample size; conclusions cannot be 
drawn 
Note. From Johns Hopkins nursing evidence-based practice model and guidelines p. 90, by R.P. 
Newhouse, S.L. Dearholt, S.S. Poe, L.C. Pugh, & K.M. White, 2007. Indianapolis, IN: Sigma 
Theta Tau International. 
 
 
Clinical Guidelines 
Nursing clinical guidelines by Rolley, Salamonson, Wensley, Dennison, and Davidson 
(2010) in Australia address peri-procedural care of PCI patients.  Although no clear bedrest 
duration was recommended in the guidelines, times from 2 hours to 4 hours were graded as a "D" 
recommendation, meaning evidence is weak and recommendations should be applied with 
caution. Consensus was based on expert opinion only. 
Theoretical Framework 
The studies synthesized for this literature review cite patient comfort and safety as 
primary endpoints but none clearly delineate a theoretical framework. Im and Meleis (1999) 
discussed the disconnect clinicians may feel between grand theories and actual clinical practice 
of nursing and the need for scholars to consider the increasing patient complexity, diversity and 
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multiple factor complications. Situation specific theories are defined as theories "that focus on 
specific nursing phenomena that reflect clinical practice and that are limited to specific 
populations or to particular field of practice" (Im & Meleis, 1999, p. 13). This approach to 
developing a situation-specific theory easily translates to care of the AFCA patient and the 
dynamic nature of evolving knowledge of post procedure bedrest and application of this growing 
evidence. With the emergence and increasing use of NOACs coupled with the growing practice 
of AFCA, a clinically specific nursing theory is appropriate for use. The situation-specific theory 
is put in social and historical context, which clearly is in line with the practice needs of nursing 
caring for this patient population. Bedrest duration has evolved and shortened in DCC and PCI 
patients and will continue to evolve in AFCA patients as further research and investigations are 
performed. A clear connection between research and practice is present in situation-specific 
theories, and this will be necessary to build the body of knowledge for the appropriate bedrest 
duration for AFCA on NOACs. Patient diversity and individual traits will limit generalizability 
of all findings of appropriate bedrest duration as the authors propose in a situation-specific 
theory (Im & Meleis, 1999). 
Summary 
 Although though there is no evidence to date regarding duration of bedrest post-AFCA 
and either complications or patient satisfaction, there is compelling evidence regarding other 
femoral vascular access procedures. Because of the similarities in the procedures themselves 
with respects to vascular access as well as in the post-procedure precautions, it is reasonable to 
conclude that the same would be true of the outcomes with respect to bedrest. Evidence 
supporting NOACs in AFCA with safety and efficacy in the periprocedural time is surfacing, 
there is a tremendous need to give nursing the tools to care for these patients.  As AFCA 
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becomes more widely performed on patients taking NOACs, literature regarding best nursing 
practice is crucial to provide high quality patient care.  Minimizing patient discomfort including 
back pain and urinary issues, and safely managing femoral vascular access site complications is 
tantamount to best nursing practice.  This project examines ongoing bedrest practices as a risk 
factor for complications and satisfaction in patients undergoing invasive femoral venous and 
arterial access in AFCA while taking NOACs. 
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Chapter III: Methods 
 This chapter includes a description of the design setting and sample used in this quality 
improvement project. This is followed by a discussion of data collection procedures and issues 
related to the protection of human subjects. 
Design 
This was a quality improvement (QI) project evaluating primary and secondary outcomes 
based on the duration of bedrest in patients who have undergone atrial fibrillation catheter 
ablation while on novel oral anticoagulants.  
Setting 
 The setting for this project was a 249-bed teaching hospital in the southeastern United 
States. Approximately 15 to 20 patients undergo elective AFCA procedures each month, of 
which approximately 60% are taking NOACs. The procedures are performed by two 
electrophysiologists. Immediate post procedure care occurs in a 10 bed holding bay of the 
cardiac catheterization lab with subsequent transfer to a 23 bed telemetry unit with a 1 to 4 nurse 
to patient ratio for overnight observation.   
Current Practice 
 Immediately following the procedure, patients are in the post-op holding area while they 
awaken from anesthesia and undergo sheath removal and manual compression to achieve 
hemostasis. Post-procedure care is carried out according to standard hospital protocols as 
directed by individual physician orders. After manual compression and hemostasis is attained, a 
FemoStop compression device is applied to the groin with 80mm Hg inflation and 10mmHg 
reduction hourly over 8 hours (see Appendix A). The duration of bedrest depends on the 
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physician performing the procedure. Physican A allows his patients to ambulate at the time of 
FemoStop® deflation and removal. Physician B requires an additional 4 hours of bedrest before 
ambulation.   
 Nurse practitioners (NPs) are in-house overnight and are the primary providers as first 
call during the patient's observation status following the procedure after receiving sign out from 
the physician. The role of the NP includes entering post-procedure orders, ordering home 
medications, performing assessments of the puncture site, treating pain, monitoring for bleeding 
and urinary complaints, and performing the discharge the following morning. The physician 
rounds on the patient the following morning and issues are generally discussed at that time
 The details of the AFCA procedure are recorded on a standard EP Pre/Post Checklist that 
is not a permanent part of the patient's medical record (see Appendix A). This checklist includes 
the procedure and the name of the physician performing it, medical history, height, weight, lab 
results, OAC and when last taken, intraoperative medications and anticoagulants administered. 
The sheath sizes and locations and times of hemostasis are recorded with ambulation time. 
Further information recorded on this sheet includes the vital signs, groin/site checks, bleeding 
complications, FemoStop management, and pulses. This sheet is used by nursing staff to 
transition care from the post-op holding area to the telemetry unit where the patient will stay 
overnight.  
Sample 
 A convenience sample of 30 patients taking NOACs and undergoing AFCA between 
February 3, 2014 and April 30, 2014 was collected for analysis. Exclusion criteria included 
difficult vascular access in the EP lab or significant rebleeding requiring additional manual 
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compression with sheath removal in the holding bay prior to transfer to the nursing unit. All 
patients undergoing AFCA on NOACs were eligible for inclusion. 
Procedures 
       This quality improvement project did not affect the routine post-procedure care of patients 
undergoing AFCA. Enrollment of patients took place either pre- or post-operatively in the cath 
lab holding bay or the patient room. This was determined based on scheduling and flow of 
patients. An oral consent and signed authorization to access private health information was 
obtained by either the PI or co-investigator authorized to do so. EP Pre/Post Checklists were 
collected at the time of discharge by the nurse practitioner and deidentified by the principle 
investigator (PI) prior to data entry.  Each record was assigned a participant code number at that 
time. Additional information collected by the NP the morning following the procedure using the 
Post-EP Procedure Assessment and using the same participant code number (see Appendix B). 
The recorded information included time of ambulation, bleeding complications, and patient 
complaints of urinary discomfort or back pain.  
 Final assessment of bleeding outcome and presence of a hematoma was evaluated by 
direct visualization, palpation, and auscultation of the groin puncture sites after removal of all 
dressings by the NP. Nursing staff notified NP's during the night if bleeding occurred with first 
ambulation or was noted with groin checks. The patients' urinary complaints and back pain was 
evaluated by questioning of patient and nurse at time of NP discharge visit the following 
morning. Urinary complaints included burning, difficulty with urinating on bedpan, and inability 
to void requiring urinary catheterization. Back pain was evaluated by the use of pain medication 
and patient verbalization of complaints of back pain. Bedrest duration following hemostasis was 
recorded by the nursing staff or NP at time of collection of data sheets on morning of discharge. 
 24 
The patients on the shortened bedrest track often remained in bed for a prolonged time, not only 
for bleeding reasons. These data were routine data already collected during routine post-
procedure assessment and patient care prior to discharge.   
 The staff collecting the data was trained by the PI to ensure the completion and retention 
of the data collection sheets (see Appendix C). Frequent reminders to ask these questions at time 
of patient discharge and assist in data collection was provided to the NP team involved in this 
role through flyers (see Appendix D) and verbal cues as well as the posting and distribution of 
the Post EP Procedure Assessment form in the cath lab holding area, the NP office, and the 
nursing unit where care for these patients was provided. These questions of the patient were 
routine questions of current practice by both nursing staff and NPs when discharging the patient.  
Protection of Human Subjects and Ethical Considerations 
 Application to the institutional review board (IRB) was performed and approval was 
obtained for minimal risk status for one year. Only deidentified data was collected prospectively 
with no change in usual care practices. The hospital served as the authorized IRB of record for 
the University of North Florida (UNF) IRB approval. Patients provided an oral consent to 
participate in the study (see Appendix E) and signed and received a copy for permission to allow 
investigators access to their personal health information (see Appendix F). 
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Chapter IV: Results 
 This chapter includes a description of the sample and delineation of the sample 
characteristics. This is followed by an overview of the results with respect to primary and 
secondary outcomes related to duration of bedrest.  
Sample Characteristics 
 A total of 30 patients underwent atrial fibrillation catheter ablation while on novel oral 
anticoagulants during the study period. Thirty (100%) were invited to participate in the study and 
30 (100%) consented. Participants ranged in age from 45 to 77 (M =66.5; SD = 6.7).  Body mass 
index ranged from 23.2 to 39.2 (M = 30.7; SD = 5.3). The actual time in bed ranged from 6 hours 
and 9 minutes to 16 hours and 40 minutes (M = 10 hours and 6 minutes, SD = 3 hours, 18 
minutes). The majority of the participants were males taking rivaroxaban as their NOAC. 
Twenty-two patients (73.3%) were placed on the shortened bedrest track of 8 hours as 
ordered by the physician, and 8 (26.7%) were on prolonged bedrest ordered for 12 hours. These 
orders were placed based on physician preference. Because of a variety of factors, the actual 
length of time in bed varied within both groups. The actual time in bed exceeded the ordered 
times due to NP, nursing or patient preferences, time that the procedure was completed, and 
sleeping through the time allowed for ambulation. Thus, 15 patients (50%) were actually on 
shortened bedrest (≤ 8 hours) and 15 (50%) were on prolonged bedrest (> 8 hours). See Table 4.1 
for a description of sample characteristics by actual bedrest duration.  
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Table 4.1 
Sample Characteristics by Actual Bedrest Duration Group 
Characteristic 
Shortened Bedrest 
< 8 hours  
Prolonged Bedrest 
> 8 hours 
N = 22 73% N = 8 27% 
Gender     
Male (N = 23) 17 77% 6 75% 
Female (N = 7) 5 23% 2 25% 
NOAC     
Rivaroxaban (N = 14) 11 50% 3 37.5% 
Apixaban (N = 9) 6 27% 3 37.5% 
Dabigatran (N = 7) 5 23% 2 25% 
  
Outcomes 
Primary Outcomes 
Primary outcome data were analyzed according to both physician-ordered bedrest 
duration groups and actual time in bed (see Table 4.2). There were 5 cases of bleeding after 
ambulation requiring additional bedrest and manual compression. The bleeding occurred in 5 
patients: 3 patients in the shortened bedrest track and 2 patients in the prolonged bedrest track. 
One patient in the shortened bedrest track had a post-operative hematoma from an inadvertent 
arterial puncture and required additional testing of complete blood count (CBC), but suffered no 
re-bleeding with shortened ambulation. Of the 5 patients that bled, only 1 was in bed for eight 
hours or less, and the remaining 4 had bedrest durations exceeding 8 hours (M = 10.6; SD= 3.6) 
due to the bleeding or reported “oozing.” Two patients from the short track had FemoStop 
reapplication with additional bedrest.    
Secondary Outcomes 
Secondary outcome data were analyzed according to ordered and actual bedrest duration 
groups (see Table 4.3). Secondary outcome measurements included urinary complaints of 
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Table 4.2 
Primary Outcomes by Physician-Ordered Bedrest and Actual Time in Bed 
 
Complication 
Physician-Ordered Bedrest Actual Bedrest 
≤ 8 hours  > 8 hours ≤ 8 hours > 8 hours 
 N = 22 73% N = 8 27% N = 15 50% N = 15 50% 
Bleeding 3 14% 2 25% 0 0 5 33% 
Hematoma 1 4.5% 0 0 1 6.7% 0 0 
 
difficulty requiring catheterization, hematuria frequency, urgency, and pain and back pain while 
on bedrest. Four patients had urinary complaints: 3 patients on physician-ordered shortened 
bedrest track, and 1 on prolonged track. Only one patient with a urinary complaint was actually 
in bed for 8 hours or less (M = 11; SD = 3.1). Three patients required urinary catheterization (1 
with shortened bedrest; 2 with prolonged bedrest) and one patient had burning (prolonged 
bedrest) with first urination that resolved spontaneously.  
Table 4.3 
 
Secondary Outcomes by Physician-Ordered Bedrest and Actual Time in Bed 
 
Complication 
Physician-Ordered Bedrest Actual Bedrest 
≤ 8 hours  > 8 hours ≤ 8 hours > 8 hours 
 N= 22 73% N= 8 27% N = 15 50% N =15 50% 
Urinary 
Complaints 
2 9% 2 25% 1 6.7% 4 26.7% 
Catheterization 2 9% 2 25% 1 6.7% 3 20% 
Back Pain 10 45% 0 0 8 53.3% 2 13.3% 
 
Ten patients of the entire sample complained of back pain while on bedrest and were all 
physician ordered to be on the shortened bedrest track. Two patients were actually in bed longer 
than 8 hours (M = 8.8; SD = 1.8). Three patients suffered from chronic back pain, 5 patients 
rated their pain on a Likert scale from 3/10 to 10/10 and 5 patients had no pain scale rating 
recorded. One patient required IV narcotics and the remaining patients were treated with oral 
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medications, repositioning, and ambulation.  One patient complaining of back pain remained in 
bed for 14 hours at the nurse's recommendation.  
Associations between Actual Bedrest Duration and Outcomes 
 Fisher’s Exact test showed no statistically significant difference in bleeding outcomes by 
actual bedrest duration group (p= 0.39), gender (p= 0.56) or specific NOAC (p=0.27). Similarly, 
the Wilcoxon rank sum found no significant difference in bleeding by age (p=0.65), or BMI 
(p=0.7).  
Fishers' Exact test showed no statistically significant difference in back pain outcomes by 
gender (p= 0.66) or NOAC (p=1.0). Similarly, the Wilcoxon rank sum test found no statistically 
significant difference in back pain by age (p=0.28) or BMI (p=0.96). There was near statistically 
significant difference in back pain by actual time in bed (p= 0.07). Fishers' Exact test showed no 
statistical significant difference in urinary complaints by specific NOAC (p= 1.0), and Wilcoxon 
rank sum showed no statistical difference on absolute time in bed (p=0.46). 
Summary 
 This study was small and underpowered yet is the beginning of gathering data about 
outcomes of bleeding, urinary complaints, and back pain on patients undergoing AFCA on 
NOACs. There was no statistically significant advantage to prolonged bedrest duration related to 
bleeding. No adverse events were recorded with the shortened bedrest patients in the immediate 
post-operative times, and bleeding occurred almost equally in both tracks of patients. There was 
no clear advantage to shortened bedrest in terms of back pain or urinary complaints.  
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Chapter V: Discussion 
 Bedrest duration following AFCA is variable and evidence is lacking for the optimal time 
needed to minimize bleeding complications. The question is further compounded by the peri-
procedural use of NOACs and limited knowledge exists on potential bleeding complications. 
This project to evaluate bedrest duration and bleeding among AFCA patients taking NOACs was 
undertaken to add to the lacking body of evidence to guide best nursing practice. The goal was to 
compare bleeding differences based on bedrest duration following the procedure. This chapter 
presents a discussion of the findings of this project in the context of previous evidence and a 
delineation of the limitations of the project. This is followed by identification of implications for 
clinical practice and for future research.    
Relation to Other Evidence 
 The literature review found no evidence to support an established amount of bedrest in 
the AFCA patient population, but a plethora of high-level research in a similar population of 
cardiac catheterization and PCI patients with progressively shortened bedrest duration was 
reviewed. The existing research was exhaustive and conclusive that shortened bedrest duration 
from over 12 hours reduced to less than 4 hours, was safe and efficacious following both DCC 
and PCI procedures with femoral vascular access (Chair et al., 2008; Kim et al., 2013; 
Mohammady et al., 2013; Tongsai & Thamlikithul, 2012). In similarity to prior research, the 
current study, comparing 8 hours to longer than 8 hours showed no difference in bleeding 
outcomes with shortened bedrest. The 8 hour timeframe was studied based on performing 
physician preference of post procedure care. The literature on early ambulation in DCC and PCI 
patients has been evolutionary and the current study begins the body of knowledge necessary to 
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investigate bedrest duration and bleeding in the AFCA patient population (Keeling et al., 1994; 
Keeling et al., 1996; Keeling et al., 2000; Reynolds et al., 2003; Searle & Hoff, 2000; Vaught & 
Ostrow, 2001).  
 Similarly, the current study results were not statistically significant for urinary complaints 
related to bedrest duration as in prior research (Chair et al., 2012). In the current study, urinary 
complaints were present almost equally in the shortened and prolonged bedrest track patients. 
Back pain was statistically significant in the physician-ordered shortened bedrest track patients in 
the current study, and near statistical significance based on actual time in bed. Back pain was the 
most common complaint reported among all patients, similar to previous research (Chair et al., 
2012; Gianakos et al., 2004).  
 One difference among the procedures is that DCC and PCI access involves a femoral 
artery access with AFCA requiring femoral venous access.  Both procedures are cared for pre 
and post by the same nursing staff in the same catherization lab holding area. Femoral access 
vascular hemostasis is achieved similarly following sheath removal with the same general 
bedrest, limb immobilization, and limitations of head of bed elevation restrictions on both sets of 
patients. Both procedures may require anticoagulation peri-procedurally, thus increasing the risk 
of bleeding.  
 There was no statistically significant advantage to prolonged bedrest duration related to 
bleeding. No adverse events were recorded with the shortened bedrest patients in the immediate 
post-operative times, and bleeding occurred almost equally in both tracks of patients. There was 
no clear advantage to shortened bedrest in terms of back pain or urinary complaints. 
Limitations 
 31 
 The sample size is small (n=30) and the results are not generalizable, but adequate to 
portray clinical practice at this particular facility and are representative of the population 
undergoing the procedure at this hospital. There are many possible confounding variables with 
this study, including use of IV unfractionated heparin in varying doses, sheath size, physician 
technique, procedure duration time, number of prior femoral vascular access procedures, and 
varying times of medication administration peri-procedurally. Other confounding variables may 
include patient characteristics of age, gender, chronic back pain, and BMI.  
 Defining bleeding and hematoma consistently was a limitation of the study. With 
multiple NPs, nurses, and cath lab staff involved in caring for these patients, the perception and 
definition of bleeding was variable. A valid and reliable hematoma measurement tool was 
lacking and reliance upon accurate measurement by the nurse or NP was required in this study. 
Also, bleeding outcome could be better quantified to determine if it was significant to require 
additional bedrest. Bleeding is a subjective nurse measurement and some nurses viewed any 
blood on the dressing, even if dried, as a reason to postpone patient ambulation.  
 A perception of bleeding complications with patients on NOACs continues to be 
prevalent in this facility. In some cases, nursing would lengthen the bedrest duration based on 
their beliefs. The time of the procedure also likely affected the time of ambulation. Often, the 
patient would be allowed out of bed at midnight but would choose to sleep through until the 
morning.  
 Pain assessment and measurements were also variable and lacking in detail. Some nurses 
recorded the pain complaints, scales to assess, treatments, and responses to treatment, and others 
were not clearly recorded or were lacking details. Due to the nature of the procedure and the 
positioning required, many back pain complaints may have been overreported. Similar problems 
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existed for recording urinary complaints and treatments. There was not a clear way to report and 
record urinary complaints and treatments. 
Implications for Practice 
 The findings support the hypothesis that shorter, or traditional bedrest duration of 8 
hours, compared to prolonged bedrest of 12 hours or longer, did not increase bleeding 
complications. These findings are useful in guiding nursing practice in caring for the patients 
post procedurally. A standardized, post AFCA bedrest duration of 8 hours is sufficient to 
maintain hemostasis in patients on NOACs. There was no benefit to maintain bedrest longer than 
8 hours to minimize bleeding complications in this study sample. There was no less reported 
back pain in the shortened back pain track and urinary complaints were similar in both groups.  
 The implications for nursing practice are important in changing practice in our institution 
to a standard of post procedure AFCA bedrest duration care. The results represent hard data that 
lengthened bedrest does not change the bleeding outcomes in this patient population. This data 
collection will be continued through the year and further analyzed by the stakeholders to 
collectively determine a standard of care. The findings will be submitted for presentation at the 
annual Heart Rhythm Society in May 2015 and submitted for publication in electrophysiology 
nursing literature.  
Implications for Research 
 The implications for research include the need for well-designed randomized controlled 
trials to evaluate well-defined variables in the AFCA patient population and the amount of 
bedrest duration needed to minimize bleeding complications. This QI project should be the 
beginning of further research to evaluate post procedure bedrest duration in AFCA patients on 
NOACs. Future research may further analyze the role of intra-procedural use and amounts of 
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unfractionated heparin, femoral access sheath sizes, patient characteristics of age, gender, BMI, 
and chronic back pain. A reliable and validated bleeding and hematoma measurement tool would 
be useful to quantify bleeding. Consistent use of a Likert pain scale for back pain would help 
measure this outcome more accurately. Assessment of treatment response to interventions of 
back pain should also be measured. Further interventions to minimize back pain in all post 
operative AFCA patients should be investigated in future research, as this problem was more 
common in shorter bedrest durations. Clear orders of bedrest duration tracks should be 
standardized to minimize confusion among nursing and provider staff with sufficient and 
ongoing education to ensure understanding. 
Conclusion 
The most important finding in this QI project was identification of the lack of evidence 
on bedrest duration following the AFCA. The project further studied the population of patients 
taking NOACs, as these drugs are quickly replacing the use of warfarin. With the increasing 
prevalence of AF and the widely performed AFCA as a viable treatment option, nursing practice 
must strive to offer evidence based care of these patients. As the AFCA procedure continues to 
evolve with increased use of NOACs, smaller vascular access sheath sizes, shorter procedure 
times, and more experienced operators, nursing care must be challenged to provide the best care 
of these patients. As bedrest duration has shortened over decades in the DCC and PCI patient 
populations while maintaining safe practice, it is hoped that the same may occur with AFCA 
patients. 
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Appendix A 
Procedure Checklist 
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Appendix B 
Patient Measurement Outcomes 
Question Y N Describe 
Did pt have rebleed requiring add'l bedrest?    
Hematoma formation larger than 5 cm?      
Was add'l testing, blood transfusion, or surgical consult 
required? 
   
Did pt complain of back pain while on bedrest restriction? 
     -1-10 Pain scale to describe most severe pain 
   
Did patient have complaints of urinary burning, frequency, 
bleeding, inability to void, and/or reinsertion of urinary 
catheter 
   
 
ACTUAL TIME OF AMBULATION_________________________ 
PATIENT BMI__________ 
ADDITIONAL COMMENTS______________________________________ 
CATH LAB STAFF: PLEASE ATTACH TO EP/CATH LAB HANDOFF SHEET (PURPLE 
WORKSHEET) AND INCLUDE WHEN PT TRANSFERS TO FLOOR 
FLOOR NURSING STAFF: PLEASE GIVE THIS SHEET TO CARDIOLOGY ARNP DAY 
OF DISCHARGE OR PLACE IN COLLECTION BIN AT 2N NURSING STATION 
 
QUESTIONS PLEASE DIRECT TO: LYNN MCWHIRTER, PI –OR-  
CO-INVESTIGATORS: Not a part of permanent patient record 
 
Patient label        Date 
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Appendix C 
 
NP QI Project Training 
 
Novel Oral Anticoagulants: Bedrest and Bleeding in Patients Undergoing  
Atrial Fibrillation Catheter Ablation 
 
No change in practice is required for this project.  
 
-Physician 1 patients will continue on standard post-procedure protocol of bedrest until 
FemoStop pressure is completed at 8 hours following femoral vascular access hemostasis.  
 
-Physician 2 patients will remain on bedrest an additional 4 hours following FemoStop pressure 
completion for a minimum of 12 hours.  
 
1) Enroll patients undergoing AFCA on NOACs for inclusion into project-no informed consent 
required 
 a) Exclusion criteria: 
 -Difficult vascular access reported by physician 
 -Rebleeding or hematoma prior to transfer to floor as reported by nursing staff 
 
2) Collect purple EP worksheet and 2nd page questionnaire at time of discharge 
 
3) Review questions and answer/complete from review of chart  
  
4) Place forms in "labeled collection bin" in PI file cabinet 
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Appendix D 
Nursing Staff Information 
AFib Ablation Patients Bedrest Duration Study 
Of Patients on Novel Oral Anticoagulants 
(Dabigatran, Rivaroxaban, Apixaban) 
 Study purpose 
o To standardize post afib ablation bedrest  
o Evaluate bleeding outcomes in different bedrest durations among afib 
ablation pts on NOACs 
o 3 month study: Feb, March, April 
o Secondary measurements: Back pain, urinary complaints 
 Usual care of patients 
o Physician A patients remain on bedrest for 8 hours following sheath 
removal and hemostasis 
o Physician B patients remain on bedrest for 12 hours following sheath 
removal and hemostasis 
 Please write time patient ambulated OOB on handoff worksheet  
 Additional questions to be asked at time of discharge and recorded on attached 
sheet 
o Did pt have rebleed requiring add’l bedrest? 
o Did pt have hematoma >5 cm? 
o Was add’l testing, blood transfusion, or surgical consult required? 
o Did pt complain of back pain while on bedrest restriction? 
 Use 1-10 VAS Scale to rate 
o Did pt have urinary complaints: inability to void, require I&O cath, burning, 
frequency, bleeding? 
 Please save purple handoff sheets and questions/answers in bin at 2N A nursing 
station for collection or give to a study investigator 
 PI 
Co-Investigators:  
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Appendix E 
 
Oral Consent Script 
 
 
Protocol Title: Novel oral anticoagulants: Bedrest duration and bleeding among atrial fibrillation 
ablation patients  
IRB #:XXXXXX 
Principal Investigator: XXXXXXX 
 
You are being asked to participate in a research study about bleeding outcomes, back pain, and 
urinary complaints in atrial fibrillation ablation patients taking novel oral anticoagulation. 
 
If you agree to participate you will be asked to answer simple questions about back pain and 
urinary complaints. Your age, gender, and body mass index will be recorded as well as your 
answers to the questions. If you had bleeding from your access sites, this will be recorded. We 
will not link the information to your identity and you will remain anonymous. You will not 
receive payment for your participation. 
 
The risks associated with the research study are not increased. These are the questions we would 
ask if you are not included in this study project. Your care will remain the same whether you are 
in the study or not. There should not be an increase in your time, discomfort, or confidentiality if 
you agree to participate. 
 
The benefits which may reasonably be expected to result from this research study will not 
directly affect your stay but it is hoped to streamline care in the future 
 
Please understand your participation is voluntary and you have the right to withdraw your 
consent or discontinue participation at any time without penalty.  Specifically, your current or 
future medical care at the XXXX will not be jeopardized if you choose not to participate.  
 
If you have any questions about this research study you can contact me at 555-5555.  If you have 
any concerns, complaints, or general questions about research or your rights as a participant, 
please contact the XXX Institutional Review Board (IRB) to speak to someone independent of 
the research team at 555-555-55555 or toll free at 555-555-5555.   
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Appendix F 
 
HIPAA Authorization to Use and Disclose Protected Health 
Information 
Name and Clinic Number 
TITLE 
Novel oral anticoagulants: Bedrest duration and bleeding among atrial fibrillation ablation patients 
IRB # XXXXXXX 
RESEARCHER 
Lynn McWhirter and colleagues 
PROTOCOL LAST APPROVED BY IRB 
January 31, 2014 
THIS FORM APPROVED 
January 31, 2014 
During this research, information about your health will be collected. Under Federal law called 
the Privacy Rule, health information is private. However, there are exceptions to this rule, and 
you should know who may be able to see, use and share your health information for research and 
why they may need to do so. Information about you and your health cannot be used in this 
research study without your written permission. If you sign this form, it will provide that 
permission. You will be given a copy of this form. 
 
Health information may be collected about you from: 
• Past, present and future medical records.  
• Research procedures, including research office visits, tests, interviews and questionnaires. 
 
This information will be used and/or given to others to: 
• • •Do the research. Report the results. See if the research was done correctly. 
If the results of this study are made public, information that identifies you will not be used. 
 
Your health information may be used or shared with: 
• XXXXX research staff involved in this study. 
 
Your health information may also be shared with: 
• The XXXXX Institutional Review Board that oversees the research. 
• Researchers involved in this study at other institutions.  
• Federal and State agencies (such as the Food and Drug Administration, the Department of 
 Health and Human Services, the National Institutes of Health and other United States 
 agencies) or government agencies in other countries that oversee or review research.  
• The sponsor(s) of this study and the people or groups it hires to help perform this research.  
• A group that oversees the data (study information) and safety of this research. 
 
Protection of your health information after it has been shared with others: 
XXXX asks anyone who receives your health information from us to protect your privacy; 
however, once your information is shared outside XXXX, we cannot promise that it will remain 
private and it may no longer be protected by the Privacy Rule. 
Page 1 of 2 
This Form Approved: January 31, 2014 
IRB 14-XXXX 
Not To Be Used After: January 30, 2015 
IRB FORM XXX 
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HIPAA Authorization to Use and Disclose Protected Health 
Information 
Your Privacy Rights 
You do not have to sign this form, but if you do not, you cannot take part in this research study. 
Your decision won’t change the access to medical care or any other benefits you get at XXXX 
now or in the future. 
If you cancel your permission to use or share your health information, your participation in this 
study will end and no more information about you will be collected; however, information 
already collected about you in the study may continue to be used. 
You can cancel your permission to use or share your health information at any time by sending a 
letter to the address below: 
XXXX Office for Human Research Protection ATTN: Notice of Revocation of Authorization 
XXXXX 
Alternatively, you may cancel your permission by emailing the XXX Clinic Research Subject 
Advocate at: XXXXX 
Please be sure to include in your letter or email: 
• • • 
The name of the Principal Investigator, The study IRB number and /or study name, and Your 
contact information. 
Your permission lasts until the end of this study, unless you cancel it. Because research is an 
ongoing process, we cannot give you an exact date when the study will end. 
Printed Name of Participant 
Signature of Participant 
X 
Date of Signature 
Printed Name of Representative Signing for Participant (if applicable) 
Representative’s Relationship to Participant (if applicable) 
Signature of Representative Signing for Participant (if applicable) 
X 
Date of Signature 
Page 2 of 2 
This Form Approved: January 31, 2014 
IRB 14-XXXX 
Not To Be Used After: January 30, 2015 
IRB FORM 10 
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